Drug interactions of Pomalidomide

CYP1A2 Inhibitors: Co-administration of the strong CYP1A2 inhibitor fluvoxamine in healthy subjects increased pomalidomide Cmax and AUC by 24% and 125%, respectively. Increased exposure to pomalidomide may increase the risk of exposure-related toxicities. Avoid co-administration with strong CYP1A2 inhibitors. If co-administration cannot be avoided, reduce the dose of pomalidomide.

Pomalidomide

Indications： Indicated for adults with relapsed/refractory multiple myeloma who progressed on or within 60 days of $\ge$2 prior therapies (including lenalidomide and a PI).

Scan code
Whatsapp

Medicine-related columns

Recommended Articles

There is no data under this category！

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More